4 top medtech stories you need to know in late 2017


3. Mergers and acquisition frenzy continues

medtech M&A LSNE

[Image courtesy of 드림포유 on Flickr, per Creative Commons 2.0 license]

They may not be as large as the $50 billion Medtronic-Covidien deal in early 2015, but M&A activity remains robust in the medical device industry, including Stryker making a $700 million fluorescence imaging technology play with its acquisition of Novadaq.

Meanwhile, Abbott is nearing the finish line with its previously rocky acquisition of Alere, after an amended merger was agreed to in April at a $5.3 billion price tag. (Abbott previously had some merger cold feet after a series of accounting snafus at Alere; news came out just today that Alere will pay $13 million to settle SEC accounting fraud charges.)


How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5

Speak Your Mind